hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The 10-foot-tall (3 m), bright-red sculpture stands in front of Pauling's childhood home in Portland, Oregon. Ribbon diagrams of α-helices are a prominent element in the laser-etched crystal sculptures of protein structures created by artist Bathsheba Grossman, such as those of insulin, hemoglobin, and DNA polymerase. Byron Rubin is a former protein crystallographer now professional sculptor in metal of proteins, nucleic acids, and drug molecules – many of which featuring α-helices, such as subtilisin, human growth hormone, and phospholipase A2. Mike Tyka is a computational biochemist at the University of Washington working with David Baker. Tyka has been making sculptures of protein molecules since 2010 from copper and steel, including ubiquitin and a potassium channel tetramer.
=== Monitoring and detection === The goal of most monitoring and detection processes is the rapid detection of harmful microorganisms with minimal interruption to the processing of food products. An example of a detection mechanism that relies heavily on biological processes is usage of chromogenic microbiological media.
== Physical activity == The Global Matrix 2.0 on Physical Activity for Children and Youth (2016) gave Thailand a score of D-minus (A=best, B-C-D, F=worst). The only other ASEAN country in the study of 38 nations was Malaysia, which received a score of D.
Upflow columns where input water enters from the bottom and regenerants enter from the top of the ion exchange column. Upflow regeneration where water enters from the top and regenerants enter from the bottom. In both cases, separate distribution headers (input water, input regenerant, exit water, and exit regenerant) must be tuned to: the input water quality and flow, the time of operation between regenerations, and the desired product water analysis. Counter-current deionization is the more attractive method of ion exchange. Chemicals (regenerants) flow in the opposite direction to the service flow. Less time for regeneration is required when compared to cocurrent columns. The quality of the finished product can be as low as .5 parts per million. The main advantage of counter-current deionization is the low operating cost, due to the low usage of regenerants during the regeneration process.
The formation of fossil eggs begins with the original egg itself. Not all eggs that end up fossilizing experience the death of their embryo beforehand. Fossil eggs with open tops are common and could result from the preservation of eggs that hatched successfully. Dinosaur eggs whose embryos died were likely victims of similar causes to those that kill embryos in modern reptile and bird eggs. Typical causes of death include congenital problems, diseases, suffocation from being buried too deep, inimical temperatures, or too much or too little water. Whether or not hatching was successful, burial would begin with sediments gradually entering any large openings in the shell. Even intact eggs are likely to fill with sediment once they crack under the strain of deep burial. Sometimes, though, fossilization can begin fast enough to prevent the eggs from being cracked. If the water table is high enough dissolved minerals like calcite can percolate through the pores of the eggshell. When the egg is completely filled it can become sturdy enough to withstand the weight of the overlying sediments. Not all fossil egg specimens are of complete specimens, however. Individual pieces of eggshell are much more robust than the entire egg and can be transported intact long distances from where they were originally laid. When the egg is buried deeply enough, the bacteria decomposing it no longer have access to oxygen and need to power their metabolisms with different substances.
Sources: en.wikipedia.org
== History == Romergoline was first described in the scientific literature in 1991. It was under development by Pharmacia Corporation, but its development was discontinued by the early 2000s and the drug was never marketed.
22 August A university reports the development of a driver isolation framework to protect operating system kernels, primarily the monolithic Linux kernel which gets ~80,000 commits/year to its drivers, from defects and vulnerabilities in device drivers, with the Mars Research Group developers describing this lack of isolation as one of the main factors undermining kernel security. Scientists demonstrate that tACS brain stimulation can, depending on the frequency, for one month improve (either) short-term memory or long-term memory in 65–88-years-old people. Scientists report a so far unique and unknown feature of material VO2 – it can "remember" previous external stimuli (via structural rather than electronic states), with potential for e.g. data storage. A university reports the first successful transplantation of an organoid into a human, first announced on 7 July, with the underlying study being published in February. 23 August A study reports that look-alike humans have genetic similarities, sharing genes affecting not only the face but also some phenotypes of physique and behavior, also indicating that (their) differences in the epigenome and microbiome contribute only modestly to human variability in facial appearance. Researchers introduce the concept of 'false social reality' and substantiate it by showing that (a sample of) Americans widely underestimate general public support for climate change mitigation policies by a large margin.
The wombat is a marsupial that is often considered to be the marsupial equivalent of the North American groundhog. The fossa of Madagascar looks like a small cat. Fossa have semi-retractable claws. Fossa also has flexible ankles that allow it to climb up and down trees head-first, and also support jumping from tree to tree. Its classification has been controversial because its physical traits resemble those of cats, but is more closely related to the mongoose family, (Herpestidae) or most likely the family Malagasy carnivores family, (Eupleridae). The raccoon dog of Asia looks like the raccoon of North America (hence its scientific name Procyonoides) due to its black face mask, stocky build, bushy appearance, and ability to climb trees. Despite their similarities, it is actually classified as part of the dog family (Canidae). Gliders or passive flight has developed independently in flying squirrels, Australian marsupial, lizards, paradise tree snake, frogs, gliding ants and flying fish and the ancient volaticotherium that lived in the Jurassic Period looked like a flying squirrel, but is not an ancestor of squirrels. Amynodontidae, a family of extinct rhinoceroses that are thought to have looked and behaved like squat, aquatic, hippopotamuses. Trichromatic color vision, separate blue, green and red vision, is found only in a few mammals and came about independently in humans, Old World monkeys and the howler monkeys of the New World, and a few Australian marsupials.
=== Bimatoprost and latanoprost === Latanoprost and bimatoprost are specific PGF2a analogues applied topically, and have been found to lengthen eyelashes, darken hair pigmentation and elongate hair. Bimatoprost is available as treatment for eyelash growth. Latanoprost has shown ability to promote scalp hair density and pigmentation, and is theorized to function at the dermal papilla. A study found latanoprost ineffective on eyelashes in a patient with alopecia areata. It has also been found ineffective in treatment of eyebrow hair loss.
== Description == Mikania micrantha has ribbed stems that grow up to 6 metres (20 ft) in length with 4–13-centimetre (1.6–5.1 in) long leaves that have a heart-shaped base and a pointed apex. 4.5–6.0-millimetre (0.18–0.24 in) white flowers grow in clusters.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.